A Test of Neural Inertia in Humans With Xenon

NCT ID: NCT02768727

Last Updated: 2022-07-08

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 21 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2016-04-30
• Study Completion Date: 2021-12-01

Brief Summary

The dual objectives of this study are to determine if the phenomenon of neural inertia is present in humans and to determine whether the order of neurocognitive function is invariant among anesthetic agents. This study will enroll 24 healthy volunteers, ages 20-40 years, who will receive xenon gas (concentrations ranging from 0% to 60%) delivered via inhaled route through the ENHANCER 3000.

Detailed Description

This is a multimodal, nonrandomized study of healthy subjects. After meeting enrollment criteria, subjects will receive a baseline neurocognitive testing on a computer for 15 minutes and will then receive a wrist watch actigraphy device to record their rest/activity patterns over 8-14 days. On the study day (roughly two weeks later), repeat baseline neurocognitive testing will be performed after subjects are fitted with a high density EEG head cap. The actual intervention (delivery of inhaled xenon gas in stepwise increasing followed by decreasing doses) should occur over 2 hours along with verbal tests to assess the presence/absence of consciousness at each xenon concentration. Xenon doses have been chosen specifically to evaluate the point at which individuals lose and then regain consciousness. Doses are escalated up through those used in human anesthesiology (75%) that permit surgery. After exposure, serial neurocognitive testing will occur every 30 minutes for 3 hours post emergence. Subjects are discharged from the study's intervention day to home only upon reaching standard post-anesthesia care unit criteria (modified Aldrete score ≥9). A post-procedure follow up phone call will occur within 24 hours of anesthetic exposure to ensure that the subject remains well. The individual's involvement is completed upon returning the Actigraphy watch 1 week after the exposure day. The expected duration of subject participation is 3 weeks.

Conditions

Neurocognitive Dysfunction

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: BASIC_SCIENCE
• Blinding Strategy: NONE

Study Groups

Xenon

Xenon anesthesia to determine if neural inertia is present in humans as visualized by CT imaging.

Group Type: EXPERIMENTAL

Xenon

Intervention Type: DRUG

drug given in concentrations of 0% to 60% over period of 2 hours

Interventions

Xenon

drug given in concentrations of 0% to 60% over period of 2 hours

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Healthy volunteers ages 20-40 years old
• American Society of Anesthesiologists (ASA) Physical Status I or II (i.e. healthy)
• Body Mass Index <30 kg/m2
• Easily visible uvula

Exclusion Criteria

• Any physical signs that would suggest a difficult airway (e.g. mouth opening <3cm, short distance between the chin and neck, poor mandibular subluxation, thick neck)
• History of reactive airway disease
• Current or history of neuropsychiatric disorders
• History or current use of psychotropic medications,
• History or current obstructive sleep apnea
• Current or history of cardiovascular disease or arrhythmias,
• Current or history of chronic sleep disorders
• History of postoperative nausea/vomiting
• Family history of problems with anesthesia (including but not limited to malignant hyperthermia),
• Current or history of Motion sickness
• Current tobacco use
• Current pregnancy or currently breastfeeding
• Positive urine toxicology screen
• History of seizure disorder, head injury, or brain tumor
• Alcohol consumption greater than 12 drinks per week or more than 4 drinks on any single day
• Inability to provide informed consent
• Inability to achieve mask seal on intervention day

• Minimum Eligible Age: 20 Years
• Maximum Eligible Age: 40 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

University of Pennsylvania

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Maz B Kelz, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

University of Pennsylvania

Locations

University of Pennsylvania, Perelman School of Medicine

Philadelphia, Pennsylvania, United States

Countries

United States

Other Identifiers

824229

Identifier Type: -

Identifier Source: org_study_id